Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
Dynavax Technologies Stock Quote

Dynavax Technologies (NASDAQ: DVAX)

$11.39
(-3.9%)
-$0.46
Price as of May 24, 2024, 4:00 p.m. ET

Dynavax Technologies Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
DVAX +2.80% +97.06% +14.51% -88%
S&P +27.79% +87.71% +13.41% +362%

Dynavax Technologies Company Info

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

News & Analysis

The Fool has written over 200 articles on Dynavax Technologies.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.